The current medications used to treat DKD can effectively mitigate renal fibrosis through multiple mechanisms, including controlling blood glucose levels, inhibiting the inflammatory response, antioxidant stress, and regulating cytokines (specifically, the transforming growth factor) and vascular endothelial growth factors (VEGF). The gene discussed is VEGFA; the disease is renal fibrosis.